ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000376

A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease

Identifieur interne : 000376 ( PascalFrancis/Corpus ); précédent : 000375; suivant : 000377

A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease

Auteurs : Kelvin L. Chou ; Melissa M. Amick ; Jason Brandt ; Richard Camicioli ; Karen Frei ; Darren Gitelman ; Jennifer Goldman ; John Growdon ; Howard I. Hurtig ; Bonnie Levin ; Irene Litvan ; Laura Marsh ; Tanya Simuni ; Alexander I. Tröster ; Ergun Y. Uc

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0512923

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Trouble cognitif, Pathologie du système nerveux, Dépistage, Essai clinique.

English descriptors

KwdEn :
- Clinical trial, Cognitive disorder, Medical screening, Nervous system diseases, Parkinson disease.

Abstract

Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 15`
A08	`01`	`1`	`ENG`	`@1 A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease`
A11	`01`	`1`		`@1 CHOU (Kelvin L.)`
A11	`02`	`1`		`@1 AMICK (Melissa M.)`
A11	`03`	`1`		`@1 BRANDT (Jason)`
A11	`04`	`1`		`@1 CAMICIOLI (Richard)`
A11	`05`	`1`		`@1 FREI (Karen)`
A11	`06`	`1`		`@1 GITELMAN (Darren)`
A11	`07`	`1`		`@1 GOLDMAN (Jennifer)`
A11	`08`	`1`		`@1 GROWDON (John)`
A11	`09`	`1`		`@1 HURTIG (Howard I.)`
A11	`10`	`1`		`@1 LEVIN (Bonnie)`
A11	`11`	`1`		`@1 LITVAN (Irene)`
A11	`12`	`1`		`@1 MARSH (Laura)`
A11	`13`	`1`		`@1 SIMUNI (Tanya)`
A11	`14`	`1`		`@1 TRÖSTER (Alexander I.)`
A11	`15`	`1`		`@1 UC (Ergun Y.)`
A14	`01`			`@1 Departments of Neurology and Neurosurgery, University of Michigan @2 Ann Arbor, Michigan @3 USA @Z 1 aut.`
A14	`02`			`@1 VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine @2 Boston, Massachusetts @3 USA @Z 2 aut.`
A14	`03`			`@1 Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 3 aut.`
A14	`04`			`@1 Division of Neurology, Department of Medicine, University of Alberta @2 Edmonton, Alberta @3 CAN @Z 4 aut.`
A14	`05`			`@1 The Parkinson's and Movement Disorders Institute @2 Fountain Valley, California @3 USA @Z 5 aut.`
A14	`06`			`@1 Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine @2 Chicago, Illinois @3 USA @Z 6 aut.`
A14	`07`			`@1 Department of Neurological Sciences, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 7 aut.`
A14	`08`			`@1 Department of Neurology, Massachusetts General Hospital @2 Boston, Massachusetts @3 USA @Z 8 aut.`
A14	`09`			`@1 Depratment of Neurology, University of Pennsylvania Health System @2 Philadelphia, Pennsylvania @3 USA @Z 9 aut.`
A14	`10`			`@1 Department of Neurology, University of Miami Miller School of Medicine @2 Miami, Florida @3 USA @Z 10 aut.`
A14	`11`			`@1 Department of Neurology, University of Louisville School of Medicine @2 Louisville, Kentucky @3 USA @Z 11 aut.`
A14	`12`			`@1 Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 12 aut.`
A14	`13`			`@1 Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine @2 Chicago, Illinois @3 USA @Z 13 aut.`
A14	`14`			`@1 Department of Neurology, University of North Carolina-Chapel Hill @2 Chapel Hill, North Carolina @3 USA @Z 14 aut.`
A14	`15`			`@1 Department of Neurology, University of Iowa @2 Iowa City, Iowa @3 USA @Z 15 aut.`
A14	`16`			`@1 Veterans Affairs Medical Center @2 Iowa City, Iowa @3 USA @Z 15 aut.`
A17	`01`	`1`		`@1 Parkinson Study Group Cognitive/Psychiatric Working Group @3 INC`
A20				`@1 2501-2507`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000191411680040`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 33 ref.`
A47	`01`	`1`		`@0 10-0512923`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Trouble cognitif @5 02`
C03	`02`	`X`	`ENG`	`@0 Cognitive disorder @5 02`
C03	`02`	`X`	`SPA`	`@0 Trastorno cognitivo @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Dépistage @5 09`
C03	`04`	`X`	`ENG`	`@0 Medical screening @5 09`
C03	`04`	`X`	`SPA`	`@0 Descubrimiento @5 09`
C03	`05`	`X`	`FRE`	`@0 Essai clinique @5 10`
C03	`05`	`X`	`ENG`	`@0 Clinical trial @5 10`
C03	`05`	`X`	`SPA`	`@0 Ensayo clínico @5 10`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 347`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0512923 INIST
ET :	A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease
AU :	CHOU (Kelvin L.); AMICK (Melissa M.); BRANDT (Jason); CAMICIOLI (Richard); FREI (Karen); GITELMAN (Darren); GOLDMAN (Jennifer); GROWDON (John); HURTIG (Howard I.); LEVIN (Bonnie); LITVAN (Irene); MARSH (Laura); SIMUNI (Tanya); TRÖSTER (Alexander I.); UC (Ergun Y.)
AF :	Departments of Neurology and Neurosurgery, University of Michigan/Ann Arbor, Michigan/Etats-Unis (1 aut.); VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine/Boston, Massachusetts/Etats-Unis (2 aut.); Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Division of Neurology, Department of Medicine, University of Alberta/Edmonton, Alberta/Canada (4 aut.); The Parkinson's and Movement Disorders Institute/Fountain Valley, California/Etats-Unis (5 aut.); Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine/Chicago, Illinois/Etats-Unis (6 aut.); Department of Neurological Sciences, Rush University Medical Center/Chicago, Illinois/Etats-Unis (7 aut.); Department of Neurology, Massachusetts General Hospital/Boston, Massachusetts/Etats-Unis (8 aut.); Depratment of Neurology, University of Pennsylvania Health System/Philadelphia, Pennsylvania/Etats-Unis (9 aut.); Department of Neurology, University of Miami Miller School of Medicine/Miami, Florida/Etats-Unis (10 aut.); Department of Neurology, University of Louisville School of Medicine/Louisville, Kentucky/Etats-Unis (11 aut.); Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine/Houston, Texas/Etats-Unis (12 aut.); Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine/Chicago, Illinois/Etats-Unis (13 aut.); Department of Neurology, University of North Carolina-Chapel Hill/Chapel Hill, North Carolina/Etats-Unis (14 aut.); Department of Neurology, University of Iowa/Iowa City, Iowa/Etats-Unis (15 aut.); Veterans Affairs Medical Center/Iowa City, Iowa/Etats-Unis (15 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 15; Pp. 2501-2507; Bibl. 33 ref.
LA :	Anglais
EA :	Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Trouble cognitif; Pathologie du système nerveux; Dépistage; Essai clinique
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Cognitive disorder; Nervous system diseases; Medical screening; Clinical trial
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Trastorno cognitivo; Sistema nervioso patología; Descubrimiento; Ensayo clínico
LO :	INIST-20953.354000191411680040
ID :	10-0512923

Links to Exploration step

Pascal:10-0512923

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease</title>
<author><name sortKey="Chou, Kelvin L" sort="Chou, Kelvin L" uniqKey="Chou K" first="Kelvin L." last="Chou">Kelvin L. Chou</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Neurology and Neurosurgery, University of Michigan</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Amick, Melissa M" sort="Amick, Melissa M" uniqKey="Amick M" first="Melissa M." last="Amick">Melissa M. Amick</name>
<affiliation><inist:fA14 i1="02"><s1>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, Department of Medicine, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frei, Karen" sort="Frei, Karen" uniqKey="Frei K" first="Karen" last="Frei">Karen Frei</name>
<affiliation><inist:fA14 i1="05"><s1>The Parkinson's and Movement Disorders Institute</s1>
<s2>Fountain Valley, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gitelman, Darren" sort="Gitelman, Darren" uniqKey="Gitelman D" first="Darren" last="Gitelman">Darren Gitelman</name>
<affiliation><inist:fA14 i1="06"><s1>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goldman, Jennifer" sort="Goldman, Jennifer" uniqKey="Goldman J" first="Jennifer" last="Goldman">Jennifer Goldman</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Growdon, John" sort="Growdon, John" uniqKey="Growdon J" first="John" last="Growdon">John Growdon</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Neurology, Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
<affiliation><inist:fA14 i1="09"><s1>Depratment of Neurology, University of Pennsylvania Health System</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levin, Bonnie" sort="Levin, Bonnie" uniqKey="Levin B" first="Bonnie" last="Levin">Bonnie Levin</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurology, University of Miami Miller School of Medicine</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University of Louisville School of Medicine</s1>
<s2>Louisville, Kentucky</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="12"><s1>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name>
<affiliation><inist:fA14 i1="13"><s1>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Tröster">Alexander I. Tröster</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Neurology, University of North Carolina-Chapel Hill</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Uc, Ergun Y" sort="Uc, Ergun Y" uniqKey="Uc E" first="Ergun Y." last="Uc">Ergun Y. Uc</name>
<affiliation><inist:fA14 i1="15"><s1>Department of Neurology, University of Iowa</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="16"><s1>Veterans Affairs Medical Center</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0512923</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0512923 INIST</idno>
<idno type="RBID">Pascal:10-0512923</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000376</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease</title>
<author><name sortKey="Chou, Kelvin L" sort="Chou, Kelvin L" uniqKey="Chou K" first="Kelvin L." last="Chou">Kelvin L. Chou</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Neurology and Neurosurgery, University of Michigan</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Amick, Melissa M" sort="Amick, Melissa M" uniqKey="Amick M" first="Melissa M." last="Amick">Melissa M. Amick</name>
<affiliation><inist:fA14 i1="02"><s1>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, Department of Medicine, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frei, Karen" sort="Frei, Karen" uniqKey="Frei K" first="Karen" last="Frei">Karen Frei</name>
<affiliation><inist:fA14 i1="05"><s1>The Parkinson's and Movement Disorders Institute</s1>
<s2>Fountain Valley, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gitelman, Darren" sort="Gitelman, Darren" uniqKey="Gitelman D" first="Darren" last="Gitelman">Darren Gitelman</name>
<affiliation><inist:fA14 i1="06"><s1>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goldman, Jennifer" sort="Goldman, Jennifer" uniqKey="Goldman J" first="Jennifer" last="Goldman">Jennifer Goldman</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Growdon, John" sort="Growdon, John" uniqKey="Growdon J" first="John" last="Growdon">John Growdon</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Neurology, Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
<affiliation><inist:fA14 i1="09"><s1>Depratment of Neurology, University of Pennsylvania Health System</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levin, Bonnie" sort="Levin, Bonnie" uniqKey="Levin B" first="Bonnie" last="Levin">Bonnie Levin</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurology, University of Miami Miller School of Medicine</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University of Louisville School of Medicine</s1>
<s2>Louisville, Kentucky</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="12"><s1>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name>
<affiliation><inist:fA14 i1="13"><s1>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Tröster">Alexander I. Tröster</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Neurology, University of North Carolina-Chapel Hill</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Uc, Ergun Y" sort="Uc, Ergun Y" uniqKey="Uc E" first="Ergun Y." last="Uc">Ergun Y. Uc</name>
<affiliation><inist:fA14 i1="15"><s1>Department of Neurology, University of Iowa</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="16"><s1>Veterans Affairs Medical Center</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>Cognitive disorder</term>
<term>Medical screening</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Trouble cognitif</term>
<term>Pathologie du   système nerveux</term>
<term>Dépistage</term>
<term>Essai clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cognitive impairment is common in Parkinson's  disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>15</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHOU (Kelvin L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>AMICK (Melissa M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BRANDT (Jason)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CAMICIOLI (Richard)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FREI (Karen)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GITELMAN (Darren)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>GOLDMAN (Jennifer)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GROWDON (John)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HURTIG (Howard I.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>LEVIN (Bonnie)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>LITVAN (Irene)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>MARSH (Laura)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SIMUNI (Tanya)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>TRÖSTER (Alexander I.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>UC (Ergun Y.)</s1>
</fA11>
<fA14 i1="01"><s1>Departments of Neurology and Neurosurgery, University of Michigan</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Neurology, Department of Medicine, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>The Parkinson's and Movement Disorders Institute</s1>
<s2>Fountain Valley, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Neurology, Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Depratment of Neurology, University of Pennsylvania Health System</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Neurology, University of Miami Miller School of Medicine</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Neurology, University of Louisville School of Medicine</s1>
<s2>Louisville, Kentucky</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Department of Neurology, University of North Carolina-Chapel Hill</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Department of Neurology, University of Iowa</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Veterans Affairs Medical Center</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Parkinson Study Group Cognitive/Psychiatric Working Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>2501-2507</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000191411680040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0512923</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Cognitive impairment is common in Parkinson's  disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Trouble cognitif</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cognitive disorder</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Trastorno cognitivo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dépistage</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Medical screening</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Descubrimiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>347</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0512923 INIST</NO>
<ET>A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease</ET>
<AU>CHOU (Kelvin L.); AMICK (Melissa M.); BRANDT (Jason); CAMICIOLI (Richard); FREI (Karen); GITELMAN (Darren); GOLDMAN (Jennifer); GROWDON (John); HURTIG (Howard I.); LEVIN (Bonnie); LITVAN (Irene); MARSH (Laura); SIMUNI (Tanya); TRÖSTER (Alexander I.); UC (Ergun Y.)</AU>
<AF>Departments of Neurology and Neurosurgery, University of Michigan/Ann Arbor, Michigan/Etats-Unis (1 aut.); VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine/Boston, Massachusetts/Etats-Unis (2 aut.); Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Division of Neurology, Department of Medicine, University of Alberta/Edmonton, Alberta/Canada (4 aut.); The Parkinson's and Movement Disorders Institute/Fountain Valley, California/Etats-Unis (5 aut.); Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine/Chicago, Illinois/Etats-Unis (6 aut.); Department of Neurological Sciences, Rush University Medical Center/Chicago, Illinois/Etats-Unis (7 aut.); Department of Neurology, Massachusetts General Hospital/Boston, Massachusetts/Etats-Unis (8 aut.); Depratment of Neurology, University of Pennsylvania Health System/Philadelphia, Pennsylvania/Etats-Unis (9 aut.); Department of Neurology, University of Miami Miller School of Medicine/Miami, Florida/Etats-Unis (10 aut.); Department of Neurology, University of Louisville School of Medicine/Louisville, Kentucky/Etats-Unis (11 aut.); Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine/Houston, Texas/Etats-Unis (12 aut.); Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine/Chicago, Illinois/Etats-Unis (13 aut.); Department of Neurology, University of North Carolina-Chapel Hill/Chapel Hill, North Carolina/Etats-Unis (14 aut.); Department of Neurology, University of Iowa/Iowa City, Iowa/Etats-Unis (15 aut.); Veterans Affairs Medical Center/Iowa City, Iowa/Etats-Unis (15 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 15; Pp. 2501-2507; Bibl. 33 ref.</SO>
<LA>Anglais</LA>
<EA>Cognitive impairment is common in Parkinson's  disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Trouble cognitif; Pathologie du   système nerveux; Dépistage; Essai clinique</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Cognitive disorder; Nervous system diseases; Medical screening; Clinical trial</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Trastorno cognitivo; Sistema nervioso patología; Descubrimiento; Ensayo clínico</SD>
<LO>INIST-20953.354000191411680040</LO>
<ID>10-0512923</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000376 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000376 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0512923
   |texte=   A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease

A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri